95% Of Cannabis Stocks Are Down More Than 50% In The Last Year…

During the last year, the cannabis sector has been beaten down and many high-profile operators are trading at 52-week lows.=

Although the negative trend has been a constant theme since early 2022, the size of the declines has exceeded our expectations. While we don’t plan to try and catch a falling knife when it comes to investing in the sector, we are closely following price movements and trading volume to better understand the current trend.

Today, we want to highlight the one-year performance of 20 North American cannabis companies so our readers can better understand the amount of pressure on the sector.

1. Canopy Growth (Nasdaq: CGC) (TSX: WEED) – down 78%
2. Green Thumb Industries (OTC: GTBIF) (CSE: GTII) – down approx. 60%
3. Fire & Flower Holdings Corp. (TSX: FAF) (OTCQX: FFLWF) – down more than 80%
4. Tilray Brands (Nasdaq: TLRY) (TSX: TLRY) – down approx. 65%
5. Aurora Cannabis (Nasdaq: ACB) (TSX: ACB) – down more than 80%
6. SNDL Inc. (NASDAQ: SNDL) – down more than 75%
7. Columbia Care Inc. (OTCQX: CCHWF) (CSE: CCHW) – down more than 80%
8. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) – down less than 10%
9. Cardiol Therapeutics (Nasdaq: CRDL) (TSX: CRDL) – down 65%
10. Innovative Industrial Properties, Inc. (NYSE: IIPR) – down more than 60%
11. Charlotte’s Web Holdings, Inc. (OTC: CWBHF) (TSX: CWEB) – down 70%
12. Verano Holdings (OTC: VRNOF) (CSE: VRNO) – down 70%
13. Trulieve Cannabis Corp. (OTC: TCNNF) – down approx. 75%
14. Curaleaf Holdings (OTC: CURLF) (CSE: CURA) – down 62%
15. High Tide (Nasdaq: HITI) (TSX Venture: HITI) – down 70%
16. HEXO Corp. (Nasdaq: HEXO) (TSX: HEXO) – down more than 80%
17. Cronos Group (Nasdaq: CRON) (TSX: CRON) – down 50%
18. Jushi Holdings (OTC: JUSHF) (CSE: JUSH) – down more than 80%
19. CEA Industries (Nasdaq: CEAD) – down 67%
20. GrowGeneration Corp. (Nasdaq: GRWG) – down 65%

Based on this subset of data on cannabis stocks, it is easy to recognize how challenging things have become for publicly traded cannabis companies. The best performer of the 20 operators was Jazz Pharmaceuticals which is down less than 10% in the last year.

Of the 20 cannabis companies listed, 95% of them have dropped more than 50% in the last year. 25% of the companies that are covered have fallen more than 80% in the last year and we find this to be significant.

We were surprised by the number of stocks that are down more than 70% and believe the weakness is overdone. Although we think the selloff has been too significant, we believe the sector will not turn around until some form of legislation is enacted in the United States.

If you are interested in learning about cannabis companies that we consider to be undervalued, please send an email to support@technical420.com with the subject “Undervalued Cannabis Stocks” to be added to our distribution list.

Company Relationship Disclosure

T420 is responsible for the T420 opinions provided in this disclosure except all sources or information provided by other parties were not verified or authenticated and T420 does not undertake to confirm or substantiate or be responsible for such information provided by other parties.

Any Content posted regarding a Profiled Issuer is not a solicitation or recommendation to buy, sell or hold securities. We cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. All information should be independently verified. We are not responsible for errors or omissions in our publications, and any opinions expressed are subject to change, without notice. We do not, nor are we under any obligation to undertake due diligence or investigation or authenticate and verify whatsoever regarding Profiled Issuers or any Content posted in relation thereto and we do not receive any verification from the Profiled Issuer regarding the Content we disseminate. Similarly, while we endeavor to facilitate the provision of quality information, we are not responsible for any loss or damages caused or alleged to have been caused by its use nor verify or authenticate or update such information.

This article contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “believes”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, state, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the impact of the Russia-Ukraine conflict on the global economy; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws

Share

Tags

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Technical420.com. Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.

Top Stories